Therapeutic Advances in Cardiovascular Disease This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Comparing clinical outcomes for a twelve-month trial of zotarolimus- and everolimus-eluting stents in patients with coronary artery disease: data from the THCRIC registry
Conclusions: According to our results, it could be concluded that the difference in the rate of MACE between the ZES and EES groups was not statistically significant at 12-month follow up. (Source: Therapeutic Advances in Cardiovascular Disease)
Source: Therapeutic Advances in Cardiovascular Disease - July 7, 2016 Category: Cardiology Authors: Poorhoseini, H. R., Kassaian, S. E., Hoseini, K., Saroukhani, S., Salarifar, M., Alidoosti, M., Nematipour, E., Haji-Zeinali, A. M., Amirzadegan, A., Seyyed Mohammadzadeh, M. H., Khadem Vatan, K., Aghajani, H., Sheikh Fathollahi, M., Farrokh-Eslamlou, H. Tags: Original Research Source Type: research

Early recurrence of atrial fibrillation after catheter ablation with left atrial fibrosis identified at cardiac magnetic resonance by late gadolinium enhancement
We present a case of a patient with extensive atrial fibrosis and AF recurrence. The study of late gadolinium enhancement with cardiac magnetic resonance imaging in patients with AF could be a valuable noninvasive tool for the selection of patients suitable for successful catheter ablation. (Source: Therapeutic Advances in Cardiovascular Disease)
Source: Therapeutic Advances in Cardiovascular Disease - July 7, 2016 Category: Cardiology Authors: Totaro, A., Casavecchia, G., Gravina, M., Ieva, R., Santoro, F., Grimaldi, M., Pellegrino, P. L., Macarini, L., Di Biase, M., Brunetti, N. D. Tags: Original Research Source Type: research

Cardiac ACE2/angiotensin 1-7/Mas receptor axis is activated in thyroid hormone-induced cardiac hypertrophy
Conclusion: The counter-regulatory components of the RAS are activated in hyperthyroidism and may be contributing to modulate the cardiac hypertrophy in response to TH. (Source: Therapeutic Advances in Cardiovascular Disease)
Source: Therapeutic Advances in Cardiovascular Disease - July 7, 2016 Category: Cardiology Authors: Diniz, G. P., Senger, N., Carneiro-Ramos, M. S., Santos, R. A. S., Barreto-Chaves, M. L. M. Tags: Original Research Source Type: research

Echocardiographic assessment of aortic valve annular and left ventricular outflow tract diameter in conscious and anesthetized adult sheep prior to prosthetic aortic valve implantation
Conclusion: This pilot study evaluation revealed that conscious echocardiographic assessment can play a role preoperatively in selecting potential candidates for surgical prosthetic aortic valve implantation, thereby minimizing the potential in prosthetic-native annular mismatching, which can contribute to altered LVOT function. (Source: Therapeutic Advances in Cardiovascular Disease)
Source: Therapeutic Advances in Cardiovascular Disease - July 7, 2016 Category: Cardiology Authors: Barka, N., Bourgoin, J., Grassl, E., St. Cyr, J. A. Tags: Original Research Source Type: research

Renin-angiotensin system inhibitors in patients with coronary artery disease who have undergone percutaneous coronary intervention
The percutaneous coronary intervention (PCI) procedure has become one of the pivotal options in the treatment of coronary artery disease (CAD). Although the PCI procedure has rapidly developed in China, some concerns including in-stent restenosis and dissatisfactory long-term prognosis remain unsolved. Large-scale randomized controlled clinical trials indicate that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) can reduce all-cause mortality and recurrent cardiac events in patients with CAD. ACEIs/ARBs are recommended as a fundamental treatment in the secondary prevention of CA...
Source: Therapeutic Advances in Cardiovascular Disease - June 4, 2016 Category: Cardiology Authors: Xiao-Dong, Z., Fei-Fei, L., Zhan-Peng, W., Xin-Xue, L., Zhi-Min, D. Tags: Reviews Source Type: research

Cardiac remodelling and RAS inhibition
Risk factors such as hypertension and diabetes are known to augment the activity and tissue expression of angiotensin II (Ang II), the major effector peptide of the renin–angiotensin system (RAS). Overstimulation of the RAS has been implicated in a chain of events that contribute to the pathogenesis of cardiovascular (CV) disease, including the development of cardiac remodelling. This chain of events has been termed the CV continuum. The concept of CV disease existing as a continuum was first proposed in 1991 and it is believed that intervention at any point within the continuum can modify disease progression. Treatm...
Source: Therapeutic Advances in Cardiovascular Disease - June 4, 2016 Category: Cardiology Authors: Ferrario, C. M. Tags: Reviews Source Type: research

Pharmacological interventions into the renin-angiotensin system with ACE inhibitors and angiotensin II receptor antagonists: effects beyond blood pressure lowering
Hypertension is recognized as an important risk factor for cardiovascular morbidity and mortality. Lowering of blood pressure has been shown to minimize the risk of cardiovascular events, with the majority of antihypertensives demonstrating a similar ability to reduce coronary events and stroke for a given reduction in blood pressure. Agents that modify the activity of the renin–angiotensin system (RAS) have been proposed to exhibit additional effects that might go beyond simple blood pressure lowering. The RAS is a crucial system that regulates extracellular fluid volume and blood pressure. Proposed potential benefi...
Source: Therapeutic Advances in Cardiovascular Disease - June 4, 2016 Category: Cardiology Authors: Düsing, R. Tags: Reviews Source Type: research

Mega clinical trials which have shaped the RAS intervention clinical practice
Following extensive clinical research, drugs affecting the renin–angiotensin system have been used for the treatment of patients with congestive heart failure, myocardial infarction, hypertension, diabetic nephropathy, chronic renal failure and for reducing the risk of developing major cardiovascular (CV) events. This review examines all mega trials (those involving >1000 patients) and smaller pivotal trials involving angiotensin-converting enzyme inhibitors (ACE-Is; 25 mega trials) and angiotensin receptor blockers (ARBs; 27 mega trials) to provide perspective on the huge database of evidence that has accumulated...
Source: Therapeutic Advances in Cardiovascular Disease - June 4, 2016 Category: Cardiology Authors: Düsing, R. Tags: Reviews Source Type: research

Vascular ageing and interventions: lessons and learnings
This review discusses the relationship between elevated blood pressure, hypertension, arterial stiffness and hence vascular ageing. This is a complex process and the majority of treatments target the consequences of this, rather than the pathophysiology of ageing itself. This is because preventing vascular ageing from occurring is complex and would require very early intervention and lifelong treatment. The process of arteriosclerosis is known to result from reversible and irreversible functional components, and, together, these are responsible for the increased systolic and decreased diastolic blood pressure seen with adv...
Source: Therapeutic Advances in Cardiovascular Disease - June 4, 2016 Category: Cardiology Authors: Williams, B. Tags: Reviews Source Type: research

Drug discovery in renin-angiotensin system intervention: past and future
The renin–angiotensin system (RAS) plays a central role in the control of blood pressure in the body and the way this interacts with other systems is widely recognized. This has not always been the case and this review summarizes how our knowledge has evolved from the initial discovery of renin by Tigerstedt and Berman in 1898. This includes the identification of angiotensin in the 1950s to the proposed relationship between this system, hypertension and ultimately cardiovascular disease. While the RAS is far more complex than originally thought, much is now known about this system and the wide ranging effects of angi...
Source: Therapeutic Advances in Cardiovascular Disease - June 4, 2016 Category: Cardiology Authors: Williams, B. Tags: Reviews Source Type: research

Preface
(Source: Therapeutic Advances in Cardiovascular Disease)
Source: Therapeutic Advances in Cardiovascular Disease - June 4, 2016 Category: Cardiology Authors: Ferrario, C. M., Wang, J.-G. Tags: Editorial Source Type: research

Potential role of systemic thrombolysis in acute submassive intermediate risk pulmonary embolism: review and future perspectives
Submassive (intermediate risk) pulmonary embolism (PE) continues to be a significantly morbid disease process that remains unrecognized, inadequately risk stratified and suboptimally treated. Appropriate early clinical and imaging-based risk stratification represents the cornerstone for adequate therapeutic decision making, particularly for the selection of candidates who may benefit the most from systemic thrombolysis. The relevance of estimating clinical prognostic scores, in combination with imaging data, for accurate assessment of right ventricular function and laboratory biomarkers, indicative of myocardial injury for...
Source: Therapeutic Advances in Cardiovascular Disease - April 6, 2016 Category: Cardiology Authors: Teleb, M., Porres-Aguilar, M., Anaya-Ayala, J. E., Rodriguez-Castro, C., Porres-Munoz, M., Mukherjee, D. Tags: Reviews Source Type: research

Ranolazine and Ivabradine: two different modalities to act against ischemic heart disease
Among the innovative drugs recently introduced for the management of chronic stable angina, Ranolazine and ivabradine represent two most true innovations. In fact, even if both drugs act by reducing myocardial work and thus oxygen consumption, this happens by a peculiar mechanism unlike that of conventional antischemic drugs. Ranolazine mediates its antianginal effects by the inhibition of cardiac late sodium current. This improves myocardial relaxation favoring myocardial perfusion. Ivabradine is a selective If channel blocker and acts by reducing firing rate of pacemaker cells in the sinoatrial node, without affecting th...
Source: Therapeutic Advances in Cardiovascular Disease - April 6, 2016 Category: Cardiology Authors: Cacciapuoti, F. Tags: Reviews Source Type: research

Percutaneous coronary interventions and antiplatelet therapy in renal transplant recipients
Cardiovascular disease is the leading cause of mortality and morbidity following renal transplantation (RT), accounting for 40–50% of all deaths. After renal transplantation, an adverse cardiovascular event occurs in nearly 40% of patients; given the dialysis vintage and the average wait time, the likelihood of receiving coronary revascularization is very high. There is a significant gap in the literature in terms of the outcomes of prophylactic coronary revascularization in renal transplantation candidates. Current guidelines on myocardial revascularization stipulate that renal transplant patients with significant c...
Source: Therapeutic Advances in Cardiovascular Disease - April 6, 2016 Category: Cardiology Authors: Summaria, F., Giannico, M. B., Talarico, G. P., Patrizi, R. Tags: Reviews Source Type: research

The potential cost-effectiveness of the Diamondback 360(R) Coronary Orbital Atherectomy System for treating de novo, severely calcified coronary lesions: an economic modeling approach
Conclusions: Based on economic modeling, the recently approved coronary OAS device is projected to be highly cost-effective for patients who undergo PCI for severely calcified lesions. (Source: Therapeutic Advances in Cardiovascular Disease)
Source: Therapeutic Advances in Cardiovascular Disease - April 6, 2016 Category: Cardiology Authors: Chambers, J., Genereux, P., Lee, A., Lewin, J., Young, C., Crittendon, J., Mann, M., Garrison, L. P. Tags: Original Research Source Type: research